Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...
Immune responses against serogroups A, C, W, and Y were noninferior between the MenABCWY and MenACWY-CRM vaccines in young adults and adolescents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback